Stephens & Co. Reiterates Overweight on Veracyte, Maintains $34 Price Target
Portfolio Pulse from Benzinga Newsdesk
Stephens & Co. analyst Mason Carrico has reiterated an Overweight rating on Veracyte (NASDAQ:VCYT) and maintained a $34 price target.
October 10, 2023 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Veracyte's stock rating has been reiterated as Overweight by Stephens & Co. with a maintained price target of $34.
The reiteration of an Overweight rating by a reputable analyst like Mason Carrico from Stephens & Co. is a positive signal for Veracyte. The maintained price target of $34 also indicates confidence in the company's stock performance. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100